AIMS: To examine the effectiveness of transdermal selegiline for producing cigarette smoking abstinence. DESIGN:Adult smokers were randomly assigned to receive selegiline transdermal system (STS) or placebo given for 8 weeks. All participants received cognitive behavior therapy (CBT). Follow-ups were conducted at 25 and 52 weeks. SETTING:Community smoking cessation clinic. PARTICIPANTS: 243 adult smokers (> or =18 years of age; > or =10 cigarettes/day). MEASURES: Expired-air carbon monoxide confirmed 7-day point prevalence abstinence. FINDINGS: STS was not superior to placebo. More women than men were abstinent at 52 week follow-up (28% vs 16%, P < 0.05). Behavioral activation (BAS) moderated treatment response (P = 0.01). The survival rate through week 52 for those with high 'drive' scores on the BAS was 47% if assigned to selegiline and 34% if assigned to placebo. The survival rate for those with low 'drive scores' on the BAS was 35% if assigned to selegiline compared to 53% if assigned to placebo. CONCLUSION:Transdermal selegiline does not appear generally effective in aiding smoking cessation though there may be a selective effect in those smokers with low 'behavioral activation'.
RCT Entities:
AIMS: To examine the effectiveness of transdermal selegiline for producing cigarette smoking abstinence. DESIGN: Adult smokers were randomly assigned to receive selegiline transdermal system (STS) or placebo given for 8 weeks. All participants received cognitive behavior therapy (CBT). Follow-ups were conducted at 25 and 52 weeks. SETTING: Community smoking cessation clinic. PARTICIPANTS: 243 adult smokers (> or =18 years of age; > or =10 cigarettes/day). MEASURES: Expired-air carbon monoxide confirmed 7-day point prevalence abstinence. FINDINGS: STS was not superior to placebo. More women than men were abstinent at 52 week follow-up (28% vs 16%, P < 0.05). Behavioral activation (BAS) moderated treatment response (P = 0.01). The survival rate through week 52 for those with high 'drive' scores on the BAS was 47% if assigned to selegiline and 34% if assigned to placebo. The survival rate for those with low 'drive scores' on the BAS was 35% if assigned to selegiline compared to 53% if assigned to placebo. CONCLUSION: Transdermal selegiline does not appear generally effective in aiding smoking cessation though there may be a selective effect in those smokers with low 'behavioral activation'.
Authors: Joel D Killen; Stephen P Fortmann; Alan F Schatzberg; Christina Arredondo; Greer Murphy; Chris Hayward; Maria Celio; Deann Cromp; Dalea Fong; Maya Pandurangi Journal: Addiction Date: 2008-08 Impact factor: 6.526
Authors: Tony P George; Jennifer C Vessicchio; Angelo Termine; Peter I Jatlow; Thomas R Kosten; Stephanie S O'Malley Journal: Biol Psychiatry Date: 2003-01-15 Impact factor: 13.382
Authors: Ivan Berlin; Ian M Hunneyball; Doris Greiling; Stephen P Jones; Hermann Fuder; Hans-Detlev Stahl Journal: Psychopharmacology (Berl) Date: 2012-03-27 Impact factor: 4.530
Authors: Roberta Kahn; Liza Gorgon; Karen Jones; Frances McSherry; Elbert D Glover; Robert M Anthenelli; Thomas Jackson; Jill Williams; Cristin Murtaugh; Ivan Montoya; Elmer Yu; Ahmed Elkashef Journal: Nicotine Tob Res Date: 2011-08-16 Impact factor: 4.244
Authors: Jane E Sarginson; Joel D Killen; Laura C Lazzeroni; Stephen P Fortmann; Heather S Ryan; Niloufar Ameli; Alan F Schatzberg; Greer M Murphy Journal: Nicotine Tob Res Date: 2015-01-08 Impact factor: 4.244
Authors: Jennifer R Laude; Steffani R Bailey; Erin Crew; Ann Varady; Anna Lembke; Danielle McFall; Anna Jeon; Diana Killen; Joel D Killen; Sean P David Journal: Addiction Date: 2017-05-02 Impact factor: 6.526
Authors: Terril L Verplaetse; Andrea H Weinberger; Philip H Smith; Kelly P Cosgrove; Yann S Mineur; Marina R Picciotto; Carolyn M Mazure; Sherry A McKee Journal: Nicotine Tob Res Date: 2015-03-11 Impact factor: 4.244
Authors: Ewoud Schuit; Orestis A Panagiotou; Marcus R Munafò; Derrick A Bennett; Andrew W Bergen; Sean P David Journal: Cochrane Database Syst Rev Date: 2017-09-08